RAMM.CN - Ramm Pharma Holdings Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.5100
+0.0150 (+3.03%)
At close: 11:42AM EDT
Stock chart is not supported by your current browser
Previous Close0.4950
Open0.0000
Bid0.4400 x N/A
Ask0.5000 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume87,432
Market Cap51.369M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1150
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    RAMM Pharma announces its quarter financial results for Q2 2020

    RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:RAMM), a leader in plant-derived cannabinoid pharmaceutical products and medical product business, is pleased to announce second quarter financial results for the three and six months ended April 30, 2020. The interim consolidated financial statements and management's discussion and analysis for the period will be available on SEDAR and on www.rammpharma.com. Sales of our Pharma products have been negatively impacted by the closure of the borders with our neighbours to the north and south, Brazil and Argentina, however sales of our sanitary and medical device products saw increased sales as hospitals, clinics and pharmacies stocked up to meet the demand imposed by Covid 19, resulting in quarterly growth and improved operating results.

  • GlobeNewswire

    RAMM Pharma Corp. Announces Intention to Commence Normal Course Issuer Bid

    RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:RAMM), announces its intention to commence a normal course issuer bid (the “NCIB”), under which it may purchase up to 5% of the current number of issued and outstanding common shares of the Company (the “Common Shares”). The NCIB may commence on or about April 20, 2020 and shall expire on the 12-month anniversary of the effective date of the NCIB. All Common Shares purchased under the NCIB will be purchased on the open market through the facilities of the Canadian Securities Exchange (the “CSE”).

  • GlobeNewswire

    RAMM Pharma Corp. Announces Postponement of Filing of Interim Financial Statements

    RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:RAMM), a leader in plant-derived cannabinoid pharmaceutical products, announces that pursuant to the blanket relief granted by the Canadian Securities Administrators it will not be filing its interim financial statements for the quarter ended January 31, 2020, and  the  related  management’s  discussion  and analysis, as required by Parts 4 and  5 of National Instrument 51-102 - Continuous Disclosure Obligations (collectively, the “Interim Filings”) by the filing deadline of March 31, 2020. The Company expects to report results within the next two weeks, and is afforded a postponement up to a maximum 45-day extension pursuant to blanket relief for all market participants granted by the Canadian Securities Administrators.

  • CNW Group

    IIROC Trade Resumption - RAMM

    IIROC Trade Resumption - RAMM

  • GlobeNewswire

    RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution

    RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:RAMM), a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that the Uruguayan Ministry of Public Health, (Ministerio de Salúd Publica or “MSP”) has approved and registered XALEX™ 10 (cannabidiol) oral solution, a prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD) free of tetrahydrocannabinol (THC), for the treatment of refractory epilepsy. RAMM has also been granted a license expansion and approval by the Instituto de Regulación y Control de Cannabis (“IRCCA”) for additional proprietary cannabis-based products and to include certain products for veterinary use, further expanding the Company’s robust portfolio of product offerings to the Latin American market.

  • CNW Group

    IIROC Trading Halt - RAMM

    VANCOUVER , March 25, 2020 /CNW/ - The following issues have been halted by IIROC: Company: Ramm Pharma Corp. CSE Symbol: RAMM (All Issues) Reason: At the request of the Company Pending News Halt Time ...

  • GlobeNewswire

    RAMM Pharma Corp. Provides Details on Operational Activities to Support COVID-19 Medical Response Effort & Corporate Update

    TORONTO, March 23, 2020 -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid.

  • GlobeNewswire

    RAMM Pharma Corp. to Acquire NettaLife, a Leading Developer of Cannabis-Based Products for Pets and Large Animals

    RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:RAMM), a leader in plant-derived cannabinoid pharmaceutical products, has entered into a definitive agreement dated February 24, 2020 to acquire Glediser S.A. operating as NettaLife™ (“NettaLife”) a leading developer of cannabis-based products for pets (the “Transaction”). The NettaPet™ Dog formulation is the first of its kind to be registered by the Ministry of Agriculture, Livestock and Fisheries in Uruguay and the only registered CBD pet food product in Latin America. Commercial distribution agreements are in place for Uruguay and negotiations are in progress with Argentina and Brazil, initial sales expected in Q2 2020.

  • GlobeNewswire

    RAMM Pharma Corp. Welcomes Legalization of Medical Cannabis in Brazil

    RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:RAMM), a leader in plant-derived cannabinoid pharmaceutical products, welcomes the announcement by Brazil’s National Health Surveillance Agency (ANVISA) which establishes a legalized environment for the sale and consumption of cannabis for medical use, as announced on December 2, 2019. Permitted products are restricted to products for oral and nasal use, in tablet or liquid form, as well as oil solutions.

  • CSE New Listing - RAMM Pharma Corp. Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com
    Newsfile

    CSE New Listing - RAMM Pharma Corp. Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

    RAMM Pharma Corp. (CSE:RAMM) is one of the latest new listings on the Canadian Securities Exchange. RAMM is one of the leaders in the field of cannabinoid pharmacology and product formulation for cannabis-derived prescription drugs and registered products.For more information, please view the InvestmentPitch Media "video" which provides additional information on the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "RAMM" in the search box. Cannot view this video? ...

  • GlobeNewswire

    RAMM Pharma Corp. (formerly MTC Growth Fund-I Inc.) Announces Closing of Business Combination with RAMM Pharma Holdings Corp., Medic Plast S.A. and Yurelan S.A.; Trading Anticipated to Commence November 8, 2019

    RAMM Pharma Corp. (the “Company” or "RAMM"), formerly MTC Growth Fund-I Inc. ("MTC"), is pleased to announce that on October 28, 2019 it completed its previously announced business combination with Medic Plast S.A. ("Medic Plast") and Yurelan S.A. (“Yurelan”), and the related acquisition of RAMM Pharma Holdings Corp. ("Finco") (collectively, the "Transactions"). The common shares of the Company are expected to commence trading on the Canadian Securities Exchange (the “CSE”) under the symbol “RAMM” on November 8, 2019.